Please ensure Javascript is enabled for purposes of website accessibility

Taking the Air Out of Lincare

By Stephen D. Simpson, Simpson, – Updated Nov 16, 2016 at 2:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Lincare has been through Medicare reimbursement cuts before. The big question is: How long before growth resumes?

Lincare Holdings (NASDAQ:LNCR), provider of home oxygen and respiratory care, has been living with its shareholders under a Sword of Damocles for some time: Everybody knew that Medicare reimbursement cuts were coming for home oxygen care, but nobody knew exactly how much those cuts would be or when they'd take effect.

Although the final announcement in late March did not influence the first quarter, it will most certainly have an impact on future results. For home oxygen therapy, Medicare (acting through the Centers for Medicare and Medicaid Services and the Office of the Inspector General) implemented cuts on a state-by-state basis that average out to about an 8.6% overall cut.

That result is not as bad as some feared -- the high end of the range was in the low teens -- but many investors had seemingly talked themselves into believing that a lower cut was likely. In any event, since the cuts are on a state-by-state basis, the impact to individual companies like Lincare, Apria Healthcare (NYSE:AHG), and Rotech Healthcare is a little less obvious but should be close to that average figure.

That's not to say that the previous Medicare cuts didn't bite into Lincare's first quarter. Revenue was down 1% to about $305 million, and net income fell to about $54.6 million. According to company management, operating income, which was reported at $90 million, was hurt by $43 million because of changes in Medicare, with about $34 million in lost revenue and an additional $9 million in extra costs.

During the quarter, the company did manage to post nearly $108 million in operating cash flow and repurchased 1.6 million shares for nearly $67 million, in addition to recording $23.7 million in capital expenditures and $29.8 million spent on business acquisitions.

Lincare also added 21 centers during the first quarter (10 acquired, 11 de novo), bringing the total to 825 at the end of the quarter.

With respect to the new Medicare announcement, Lincare management believes that it will cost the company $15 million to $16 million in lost revenue, starting with the second quarter. What's more, there is still a risk that Medicare could cut the nebulizer-drug dispensing fee that currently stands at $57 per patient per month, though such a cut probably wouldn't come until 2006.

This bad news for Lincare will make profit growth difficult for some time to come. That said, Lincare has been through this before and still emerged as a growth company once management adjusted to the new realities.

Given the considerably fragmented nature of the business, and considering that these new cuts will make it even more difficult for smaller operators, Lincare will no doubt continue to pursue acquisitions as a central growth strategy. Although future Medicare cuts are still possible, investors have likely seen the worst of the storm for now. After all, lowering reimbursements beyond a level where companies like Lincare could still profit would only harm patients in the end.

For more on home health-care stocks, try these other Foolish Takes:

Fool contributor Stephen Simpson has no financial interest in any stocks mentioned (that means he's neither long nor short the shares).

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.